The field of oncology has witnessed remarkable progress in the treatment of solid tumors, yet the quest for optimal therapeutic outcomes remains a formidable challenge. Current clinical evidence underscores the superiority of combination therapies over monotherapies, as they integrate classical anticancer agents, targeted treatments, and immunomodulatory drugs to enhance effectiveness. Despite these advances, the rational design of these combinations to maximize efficacy while minimizing toxicity remains a critical objective. Additionally, the repurposing of drugs initially approved for non-cancer indications presents a promising opportunity for innovation in cancer treatment. However, understanding the mechanisms that underpin these combinations and their potential to improve patient outcomes is still an area ripe for exploration. Addressing these gaps is essential to push the boundaries of current cancer therapy and develop more effective treatment strategies.This Research Topic aims to explore rational combination therapies for solid tumors to uncover strategies that maximize therapeutic efficacy and minimize side effects. We seek to provide a platform for both clinical and preclinical studies that examine the synergy between various drugs, including those not traditionally associated with cancer treatment. Our focus is on combinations targeting tumors with specific unfavorable mutations, combinations with drugs developed for other diseases, and strategies to overcome resistance. Additionally, we aim to gain insights into the interplay between immunotherapy and targeted therapies, as well as approaches that integrate drugs affecting cell metabolism or DNA repair with traditional anticancer agents.To gather further insights in the development of rational combination therapies for solid tumors, we welcome articles addressing, but not limited to, the following themes:- Combinations targeting tumors with specific unfavorable mutations- Combining drugs initially marketed for different pathologies- Strategies to overcome drug resistance- Integrating immunotherapy with targeted therapies- Combinations of drugs that interfere with cell metabolism alongside anticancer agents- Combinations of drugs that disrupt DNA repair mechanisms with anticancer agentsManuscripts should contribute to the understanding and development of rational combination therapies, proposing innovative solutions to enhance treatment efficacy and reduce toxicity. By aggregating diverse insights and data, we aim to establish a comprehensive knowledge base that can guide future therapeutic strategies for solid tumors. Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.
The field of oncology has witnessed remarkable progress in the treatment of solid tumors, yet the quest for optimal therapeutic outcomes remains a formidable challenge. Current clinical evidence underscores the superiority of combination therapies over monotherapies, as they integrate classical anticancer agents, targeted treatments, and immunomodulatory drugs to enhance effectiveness. Despite these advances, the rational design of these combinations to maximize efficacy while minimizing toxicity remains a critical objective. Additionally, the repurposing of drugs initially approved for non-cancer indications presents a promising opportunity for innovation in cancer treatment. However, understanding the mechanisms that underpin these combinations and their potential to improve patient outcomes is still an area ripe for exploration. Addressing these gaps is essential to push the boundaries of current cancer therapy and develop more effective treatment strategies.This Research Topic aims to explore rational combination therapies for solid tumors to uncover strategies that maximize therapeutic efficacy and minimize side effects. We seek to provide a platform for both clinical and preclinical studies that examine the synergy between various drugs, including those not traditionally associated with cancer treatment. Our focus is on combinations targeting tumors with specific unfavorable mutations, combinations with drugs developed for other diseases, and strategies to overcome resistance. Additionally, we aim to gain insights into the interplay between immunotherapy and targeted therapies, as well as approaches that integrate drugs affecting cell metabolism or DNA repair with traditional anticancer agents.To gather further insights in the development of rational combination therapies for solid tumors, we welcome articles addressing, but not limited to, the following themes:- Combinations targeting tumors with specific unfavorable mutations- Combining drugs initially marketed for different pathologies- Strategies to overcome drug resistance- Integrating immunotherapy with targeted therapies- Combinations of drugs that interfere with cell metabolism alongside anticancer agents- Combinations of drugs that disrupt DNA repair mechanisms with anticancer agentsManuscripts should contribute to the understanding and development of rational combination therapies, proposing innovative solutions to enhance treatment efficacy and reduce toxicity. By aggregating diverse insights and data, we aim to establish a comprehensive knowledge base that can guide future therapeutic strategies for solid tumors. Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.